Akesobio IPO Initiation: The Tough Get Going
Akeso Biopharma Inc (1495016D CH) is a clinical-stage biopharmaceutical company with aims to address global unmet medical needs in oncology,...
556 Views
3SBio: Valuation Trap with Tell-Tale Signs of Corporate Governance Issues
3SBio is a leading pharmaceutical company in China. It has a dominant market share in two of its key products. Recently, the company's share price...
416 Views
"Buy the Worst" - A Simple Strategy to Beat the Hang Seng Index in 2020 and the Years to Come?
Based on a "Buy the Worst" strategy, we can achieve a 39pp outperformance against the HSI over the last three years. Instead, using a "Buy the...
1k Views
HK - Alibaba Most Shorted; Xiaomi, Yuhua Edu, AAC Tech, CNBM Covered
We analyse the latest SFC data released today evening on short position reporting in Hong Kong for the week ended 6 December.Total short notional...
506 Views
Hansoh Pharma's Lock-Up Expiry: Valuation and the Trade
Lock-up restriction for Hansoh Pharma's controlling shareholder, pre-IPO investors and cornerstone investors will expire on December 14th. We...
583 Views